Boundless Bio (BOLD) Competitors

$1.57 0.00 (0.00%)

Closing price 04:00 PM Eastern

Extended Trading

$1.56 -0.01 (-0.32%)

As of 06:54 PM Eastern

BOLD vs. TTRX, AADI, SPRB, IBIO, and PYRGF

Should you be buying Boundless Bio stock or one of its competitors? The main competitors of Boundless Bio include Turn Therapeutics (TTRX), Aadi Bioscience (AADI), Spruce Biosciences (SPRB), iBio (IBIO), and PyroGenesis Canada (PYRGF).

How does Boundless Bio compare to Turn Therapeutics?

Boundless Bio (NASDAQ:BOLD) and Turn Therapeutics (NASDAQ:TTRX) are both small-cap pharmaceutical preparations industry companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, profitability, earnings, valuation and media sentiment.

: In the previous week, Boundless Bio's average media sentiment score of 0.00 equaled Turn Therapeutics'average media sentiment score.
Company Overall Sentiment
Boundless Bio Neutral
Turn Therapeutics Neutral
: Boundless Bio currently has a consensus target price of $3.50, indicating a potential upside of 122.93%. Turn Therapeutics has a consensus target price of $8.00, indicating a potential upside of 116.22%. Given Boundless Bio's higher probable upside, equities research analysts plainly believe Boundless Bio is more favorable than Turn Therapeutics.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Boundless Bio
1 Sell rating(s)
1 Hold rating(s)

1 Buy rating(s)

0 Strong Buy rating(s)
2.00
Turn Therapeutics
1 Sell rating(s)

0 Hold rating(s)

1 Buy rating(s)

0 Strong Buy rating(s)
2.00
: Turn Therapeutics is trading at a lower price-to-earnings ratio than Boundless Bio, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Boundless Bio N/A N/A -$58.20M -$2.61 N/A
Turn Therapeutics N/A N/A -$3.19M -$0.16 N/A
: Turn Therapeutics' return on equity of 0.00% beat Boundless Bio's return on equity.
Company Net Margins Return on Equity Return on Assets
Boundless Bio N/A -49.73% -33.42%
Turn Therapeutics N/A N/A N/A

Company	Overall Sentiment
Boundless Bio	Neutral
Turn Therapeutics	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Boundless Bio	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Turn Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Boundless Bio	N/A	N/A	-$58.20M	-$2.61	N/A
Turn Therapeutics	N/A	N/A	-$3.19M	-$0.16	N/A

Company	Net Margins	Return on Equity	Return on Assets
Boundless Bio	N/A	-49.73%	-33.42%
Turn Therapeutics	N/A	N/A	N/A

Summary

Turn Therapeutics beats Boundless Bio on 4 of the 5 factors compared between the two stocks.

How does Boundless Bio compare to Aadi Bioscience?

Boundless Bio (NASDAQ:BOLD) and Aadi Bioscience (NASDAQ:AADI) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, risk, valuation, profitability, earnings and media sentiment.

: Boundless Bio has a beta of 0.57, suggesting that its stock price is 43% less volatile than the S&P 500. Comparatively, Aadi Bioscience has a beta of 0.68, suggesting that its stock price is 32% less volatile than the S&P 500.
: In the previous week, Aadi Bioscience had 1 more articles in the media than Boundless Bio. MarketBeat recorded 1 mentions for Aadi Bioscience and 0 mentions for Boundless Bio. Boundless Bio's average media sentiment score of 0.00 equaled Aadi Bioscience'saverage media sentiment score.
Company Overall Sentiment
Boundless Bio Neutral
Aadi Bioscience Neutral
: Boundless Bio has higher earnings, but lower revenue than Aadi Bioscience. Aadi Bioscience is trading at a lower price-to-earnings ratio than Boundless Bio, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Boundless Bio N/A N/A -$58.20M -$2.61 N/A
Aadi Bioscience $25.07M 3.93 -$65.76M -$2.35 N/A
: Boundless Bio has a net margin of 0.00% compared to Aadi Bioscience's net margin of -246.06%. Boundless Bio's return on equity of -49.73% beat Aadi Bioscience's return on equity.
Company Net Margins Return on Equity Return on Assets
Boundless Bio N/A -49.73% -33.42%
Aadi Bioscience -246.06% -71.87% -57.28%
: Boundless Bio currently has a consensus target price of $3.50, indicating a potential upside of 122.93%. Given Boundless Bio's stronger consensus rating and higher probable upside, research analysts clearly believe Boundless Bio is more favorable than Aadi Bioscience.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Boundless Bio
1 Sell rating(s)
1 Hold rating(s)

1 Buy rating(s)

0 Strong Buy rating(s)
2.00
Aadi Bioscience
0 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
: 52.1% of Aadi Bioscience shares are owned by institutional investors. 21.1% of Boundless Bio shares are owned by company insiders. Comparatively, 37.3% of Aadi Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Company	Overall Sentiment
Boundless Bio	Neutral
Aadi Bioscience	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Boundless Bio	N/A	N/A	-$58.20M	-$2.61	N/A
Aadi Bioscience	$25.07M	3.93	-$65.76M	-$2.35	N/A

Company	Net Margins	Return on Equity	Return on Assets
Boundless Bio	N/A	-49.73%	-33.42%
Aadi Bioscience	-246.06%	-71.87%	-57.28%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Boundless Bio	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Aadi Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Boundless Bio beats Aadi Bioscience on 8 of the 14 factors compared between the two stocks.

How does Boundless Bio compare to Spruce Biosciences?

Boundless Bio (NASDAQ:BOLD) and Spruce Biosciences (NASDAQ:SPRB) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, risk, valuation, profitability, earnings and media sentiment.

: Spruce Biosciences has higher revenue and earnings than Boundless Bio. Spruce Biosciences is trading at a lower price-to-earnings ratio than Boundless Bio, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Boundless Bio N/A N/A -$58.20M -$2.61 N/A
Spruce Biosciences $4.91M 16.56 -$38.97M -$51.72 N/A
: In the previous week, Spruce Biosciences had 1 more articles in the media than Boundless Bio. MarketBeat recorded 1 mentions for Spruce Biosciences and 0 mentions for Boundless Bio. Spruce Biosciences' average media sentiment score of 0.23 beat Boundless Bio's score of 0.00 indicating that Spruce Biosciences is being referred to more favorably in the news media.
Company Overall Sentiment
Boundless Bio Neutral
Spruce Biosciences Neutral
: Boundless Bio currently has a consensus target price of $3.50, indicating a potential upside of 122.93%. Spruce Biosciences has a consensus target price of $190.60, indicating a potential upside of 221.20%. Given Spruce Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Spruce Biosciences is more favorable than Boundless Bio.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Boundless Bio
1 Sell rating(s)
1 Hold rating(s)

1 Buy rating(s)

0 Strong Buy rating(s)
2.00
Spruce Biosciences
1 Sell rating(s)

2 Hold rating(s)

5 Buy rating(s)

0 Strong Buy rating(s)
2.50
: Boundless Bio's return on equity of -49.73% beat Spruce Biosciences' return on equity.
Company Net Margins Return on Equity Return on Assets
Boundless Bio N/A -49.73% -33.42%
Spruce Biosciences N/A -203.99% -127.96%
: Boundless Bio has a beta of 0.57, suggesting that its stock price is 43% less volatile than the S&P 500. Comparatively, Spruce Biosciences has a beta of 3.26, suggesting that its stock price is 226% more volatile than the S&P 500.
: 91.7% of Spruce Biosciences shares are owned by institutional investors. 21.1% of Boundless Bio shares are owned by company insiders. Comparatively, 4.3% of Spruce Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Boundless Bio	N/A	N/A	-$58.20M	-$2.61	N/A
Spruce Biosciences	$4.91M	16.56	-$38.97M	-$51.72	N/A

Company	Overall Sentiment
Boundless Bio	Neutral
Spruce Biosciences	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Boundless Bio	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Spruce Biosciences	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

Company	Net Margins	Return on Equity	Return on Assets
Boundless Bio	N/A	-49.73%	-33.42%
Spruce Biosciences	N/A	-203.99%	-127.96%

Summary

Spruce Biosciences beats Boundless Bio on 9 of the 14 factors compared between the two stocks.

How does Boundless Bio compare to iBio?

Boundless Bio (NASDAQ:BOLD) and iBio (NASDAQ:IBIO) are both small-cap pharmaceutical preparations industry companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, profitability, earnings, analyst recommendations, valuation, institutional ownership, media sentiment and risk.

: In the previous week, iBio had 1 more articles in the media than Boundless Bio. MarketBeat recorded 1 mentions for iBio and 0 mentions for Boundless Bio. iBio's average media sentiment score of 1.66 beat Boundless Bio's score of 0.00 indicating that iBio is being referred to more favorably in the news media.
Company Overall Sentiment
Boundless Bio Neutral
iBio Very Positive
: Boundless Bio currently has a consensus target price of $3.50, suggesting a potential upside of 122.93%. iBio has a consensus target price of $4.75, suggesting a potential upside of 195.03%. Given iBio's stronger consensus rating and higher probable upside, analysts clearly believe iBio is more favorable than Boundless Bio.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Boundless Bio
1 Sell rating(s)
1 Hold rating(s)

1 Buy rating(s)

0 Strong Buy rating(s)
2.00
iBio
1 Sell rating(s)

0 Hold rating(s)

2 Buy rating(s)

3 Strong Buy rating(s)
3.17
: Boundless Bio's return on equity of -49.73% beat iBio's return on equity.
Company Net Margins Return on Equity Return on Assets
Boundless Bio N/A -49.73% -33.42%
iBio N/A -71.26% -57.92%
: 7.9% of iBio shares are owned by institutional investors. 21.1% of Boundless Bio shares are owned by company insiders. Comparatively, 2.8% of iBio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
: iBio has higher revenue and earnings than Boundless Bio. iBio is trading at a lower price-to-earnings ratio than Boundless Bio, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Boundless Bio N/A N/A -$58.20M -$2.61 N/A
iBio $400K 145.46 -$18.38M -$1.00 N/A
: Boundless Bio has a beta of 0.57, meaning that its share price is 43% less volatile than the S&P 500. Comparatively, iBio has a beta of 1.23, meaning that its share price is 23% more volatile than the S&P 500.

Company	Overall Sentiment
Boundless Bio	Neutral
iBio	Very Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Boundless Bio	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
iBio	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	3 Strong Buy rating(s)	3.17

Company	Net Margins	Return on Equity	Return on Assets
Boundless Bio	N/A	-49.73%	-33.42%
iBio	N/A	-71.26%	-57.92%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Boundless Bio	N/A	N/A	-$58.20M	-$2.61	N/A
iBio	$400K	145.46	-$18.38M	-$1.00	N/A

Summary

iBio beats Boundless Bio on 11 of the 14 factors compared between the two stocks.

How does Boundless Bio compare to PyroGenesis Canada?

Boundless Bio (NASDAQ:BOLD) and PyroGenesis Canada (NASDAQ:PYRGF) are both small-cap pharmaceutical preparations industry companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, profitability, earnings, analyst recommendations, valuation, institutional ownership, media sentiment and risk.

: Boundless Bio has a net margin of 0.00% compared to PyroGenesis Canada's net margin of -115.14%. PyroGenesis Canada's return on equity of 0.00% beat Boundless Bio's return on equity.
Company Net Margins Return on Equity Return on Assets
Boundless Bio N/A -49.73% -33.42%
PyroGenesis Canada -115.14% N/A -60.81%
: Boundless Bio currently has a consensus target price of $3.50, suggesting a potential upside of 122.93%. Given Boundless Bio's stronger consensus rating and higher probable upside, analysts clearly believe Boundless Bio is more favorable than PyroGenesis Canada.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Boundless Bio
1 Sell rating(s)
1 Hold rating(s)

1 Buy rating(s)

0 Strong Buy rating(s)
2.00
PyroGenesis Canada
0 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
: 0.0% of PyroGenesis Canada shares are owned by institutional investors. 21.1% of Boundless Bio shares are owned by company insiders. Comparatively, 47.7% of PyroGenesis Canada shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
: Boundless Bio has a beta of 0.57, meaning that its share price is 43% less volatile than the S&P 500. Comparatively, PyroGenesis Canada has a beta of 0.26, meaning that its share price is 74% less volatile than the S&P 500.
: In the previous week, PyroGenesis Canada had 2 more articles in the media than Boundless Bio. MarketBeat recorded 2 mentions for PyroGenesis Canada and 0 mentions for Boundless Bio. Boundless Bio's average media sentiment score of 0.00 equaled PyroGenesis Canada'saverage media sentiment score.
Company Overall Sentiment
Boundless Bio Neutral
PyroGenesis Canada Neutral
: PyroGenesis Canada has higher revenue and earnings than Boundless Bio. PyroGenesis Canada is trading at a lower price-to-earnings ratio than Boundless Bio, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Boundless Bio N/A N/A -$58.20M -$2.61 N/A
PyroGenesis Canada $9.14M 6.78 -$21.12M -$0.05 N/A

Company	Net Margins	Return on Equity	Return on Assets
Boundless Bio	N/A	-49.73%	-33.42%
PyroGenesis Canada	-115.14%	N/A	-60.81%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Boundless Bio	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
PyroGenesis Canada	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Company	Overall Sentiment
Boundless Bio	Neutral
PyroGenesis Canada	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Boundless Bio	N/A	N/A	-$58.20M	-$2.61	N/A
PyroGenesis Canada	$9.14M	6.78	-$21.12M	-$0.05	N/A

Summary

Boundless Bio and PyroGenesis Canada tied by winning 7 of the 14 factors compared between the two stocks.

Get Boundless Bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BOLD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BOLD vs. The Competition

Export

Metric	Boundless Bio	PHARMACEUTICAL PREPARATIONS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$35.20M	$886.55M	$6.25B	$11.77B
Dividend Yield	N/A	4.84%	2.74%	5.26%
P/E Ratio	-0.60	0.96	24.91	23.23
Price / Sales	N/A	120.65	504.56	75.49
Price / Cash	N/A	20.07	43.30	53.90
Price / Book	0.36	7.60	9.67	6.69
Net Income	-$58.20M	-$4.80M	$3.55B	$332.64M
7 Day Performance	9.03%	-0.05%	1.70%	2.01%
1 Month Performance	45.37%	5.50%	5.62%	9.19%
1 Year Performance	1.29%	30.96%	34.42%	39.59%

Boundless Bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count
BOLD Boundless Bio	2.0139 of 5 stars	$1.57 flat	$3.50 +122.9%	N/A	$35.20M	N/A	N/A	64
TTRX Turn Therapeutics	N/A	$3.66 +2.8%	$8.00 +118.6%	N/A	$109.03M	N/A	N/A	2
AADI Aadi Bioscience	N/A	$4.04 -2.2%	N/A	N/A	$99.78M	$25.07M	N/A	40
SPRB Spruce Biosciences	2.3014 of 5 stars	$56.77 +2.3%	$190.60 +235.7%	N/A	$78.02M	N/A	N/A	20
IBIO iBio	4.3085 of 5 stars	$1.67 +2.8%	$4.75 +185.3%	N/A	$59.63M	$400K	N/A	100

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BOLD) was last updated on 5/5/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Boundless Bio (BOLD) Competitors

BOLD vs. TTRX, AADI, SPRB, IBIO, and PYRGF

How does Boundless Bio compare to Turn Therapeutics?

Summary

How does Boundless Bio compare to Aadi Bioscience?

Summary

How does Boundless Bio compare to Spruce Biosciences?

Summary

How does Boundless Bio compare to iBio?

Summary

How does Boundless Bio compare to PyroGenesis Canada?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BOLD vs. The Competition

Boundless Bio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Boundless Bio (BOLD) Competitors

BOLD vs. TTRX, AADI, SPRB, IBIO, and PYRGF

How does Boundless Bio compare to Turn Therapeutics?

Summary

How does Boundless Bio compare to Aadi Bioscience?

Summary

How does Boundless Bio compare to Spruce Biosciences?

Summary

How does Boundless Bio compare to iBio?

Summary

How does Boundless Bio compare to PyroGenesis Canada?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BOLD vs. The Competition

Boundless Bio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools